Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Melior Will Screen AstraZeneca Compounds For Therapeutic Activity

This article was originally published in The Pink Sheet Daily

Executive Summary

Meanwhile, the discovery firm plans to spin off a diabetes drug company with its own lead compound MLR-1023.

You may also be interested in...

Melior, Pfizer Trade Diabetes License Option For Data

Data from Pfizer on “recycled” gastric-ulcer drug will help move it into humans, Melior CEO tells “The Pink Sheet” DAILY.

Melior Discovery Signs Development Deal With Johnson & Johnson

J&J is third big pharma firm to sign on to use Melior’s in vivo theraTrace therapeutic indications screening platform.

Rare Disease Roundtable: Dealing With Pricing Pressure

Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts